Tensha Therapeutics, Inc. (extinct)

Tensha Therapeutics, Inc. (extinct)

Tensha Therapeutics, Inc. (extinct)

Overview
Date Founded

2011

Headquarters

47 Thorndike Street,Suite B1-1,Cambridge, MA 02141

Type of Company

Private

Employees (Worldwide)

10K - 1M

Industries

Hospitals & Patient Services
Biotechnology

Company Description

Tensha Therapeutics, Inc. develops small molecule bromodomain inhibitors. The firm’s product is used to treat cancer and other serious disorders. The company was founded by James Bradner in 2011 and is headquartered in Cambridge, MA.

Paths to Tensha Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Tensha Therapeutics, Inc.
Recent Transactions
Details Hidden

Roche Holding AG purchases Tensha Therapeutics, Inc. from HealthCare Ventures LLC

Details Hidden

Tensha Therapeutics, Inc. raised money in a private placement transaction

Transaction Advisors
Legal Advisor

Advised onRoche Holding AG purchases Tensha Therapeutics, Inc. from HealthCare Ventures LLC

Investors
Details Hidden

Co-Founder at C4 Therapeutics, Inc.

Details Hidden

Healthcare Ventures (HCV) invests in pre-clinical or early clinical stage, project-focused companies with the potential to transform patient care. The firm seeks to identify high potential products within academia or pharmaceutical companies and develop them into clinical proof-of-concept within capital efficient, semi-virtual organizations. They seek to generate superior returns through acquisitions by pharmaceutical and biotechnology companies. HCV invests in early-stage and emerging growth healthcare companies that have the potential for exceptional growth. The firm invests primarily in privately-owned companies. They target companies that are well-positioned to grow rapidly in value based on product development timelines, capital requirements and future demand for products. The companies HCV invests in support a broad array of technology platforms and offer late-stage products or novel innovations. The firm also looks for companies that can retain their product rights and have near-term potential cash flow. HCV expects liquidity in 3 to 5 years at a valuation in excess of 10 times invested capital. Companies should have revenues that minimize equity capital requirements and technology platforms that generate multiple products.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Tensha Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Tensha Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Tensha Therapeutics, Inc..